|
Expanded Access Program of GRASPA for treatment of patients with acute lymphoblastic leukemia unable to receive other form of L-Asparaginase: A status update (NCT02197650). |
|
|
Consulting or Advisory Role - ERYTECH Pharma |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Celgene; Sunesis Pharmaceuticals |
Research Funding - Amgen; Chugai Pharma |
|
|
No Relationships to Disclose |
|
Cecile DUMESNIL de MARICOURT |
No Relationships to Disclose |
|
|
Employment - ERYTECH Pharma |
Leadership - ERYTECH Pharma |
Stock and Other Ownership Interests - ERYTECH Pharma |
Travel, Accommodations, Expenses - ERYTECH Pharma |